Peptide profile · Healing & Recovery

Natriuretic Peptide (ANP)

Name: Natriuretic Peptide (ANP) — Peptide Information
Creator: Michael Carroll

Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Healing & RecoveryModerate human trialsResearch compound

Typical dose

0.025-0.050 mcg/kg/min continuous infusion

Once dailyCycle: Ongoing/indefiniteOnset: Moderate (1-2 weeks)

Half-life

Approximately 15-30 minutes (IV administration)

Bioavailability

100% (intravenous administration)

Molecular weight

3080.5 g/mol

Evidence level

Moderate human trials

01 · Compound profile

Scientific & efficacy data

Molecular formula

C₁₂₇H₂₀₃N₄₅O₃₉S₃

Primary benefits

Acute Fluid Management82

Reduces pulmonary congestion and fluid buildup in the lungs during acute heart failure

Hemodynamic Stabilization78

Promotes vasodilation, causing blood vessels to relax and reducing blood pressure

Symptom Relief74

Increases urine production and sodium excretion to remove excess fluid from the body

Mol. weight3080.5 g/mol

CAS numberVariable depending on salt form; carperitide CAS: 120399-20-4

PubChem16129708

Developed · 1981Research Team
Academic Research Institutions

Amino acid sequence

SSCGGSFFRKTIPQPTFVACVFG

02 · Dosing

How much do I take?

0.025-0.050 mcg/kg/min continuous infusion · continuous iv infusion

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

Starting0.0125 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursVery low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.

Standard0.025-0.050 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursGuideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.

Best time to take

Natriuretic Peptide (ANP) is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.

With food?

IV administration of Natriuretic Peptide (ANP) is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.

If stacking

Natriuretic Peptide (ANP) should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

＋ Increase if

+You've tolerated the current dose for the recommended period without significant side effects
+Therapeutic goals haven't been met at the current dose level
+Your healthcare provider recommends dose escalation based on your response
+Lab work or clinical assessments support a higher dose

－ Decrease if

−Side effects are bothersome or impacting daily life despite management strategies
−You experience any signs of an adverse reaction
−Lab results indicate the need for dose reduction
−Your healthcare provider recommends a lower dose based on your response

✓ Signs of right dose

✓Therapeutic goals being met with minimal side effects
✓Stable and consistent response to treatment
✓Lab values or clinical markers trending in the right direction
✓Good tolerance with manageable or absent side effects

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

5mg

Look here!

The weight is on the label

5mg

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

03 · Suitability

Is this right for me?

Best for managing acute decompensated heart failure with fluid overload & relieving shortness of breath caused by pulmonary congestion

Best for

Managing acute decompensated heart failure with fluid overload

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving shortness of breath caused by pulmonary congestion

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Lowering elevated blood pressure in emergency cardiac situations

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reducing the workload on the heart during acute episodes

Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for healing & recovery supportConsult your healthcare provider for alternatives to Natriuretic Peptide (ANP) based on your specific needs and medical history

Alternative healing peptidesBPC-157, TB-500 (Thymosin Beta-4), GHK-Cu

Non-peptide recovery optionsPlatelet-Rich Plasma (PRP), Collagen supplements, Physical therapy

Do not use if

Severe kidney failure with very low glomerular filtration rateRecent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressureAcute coronary syndrome or recent heart attack where vasodilation could be harmfulSevere hypotension or cardiogenic shock without proper supportive careAllergies to ANP, carperitide, or any components of the pharmaceutical formulation

Use with caution if

You are taking other medications—discuss potential interactions with your healthcare providerYou have a history of liver or kidney diseaseYou are elderly or have multiple medical conditionsYou are planning surgery in the near future—inform your surgeon about Natriuretic Peptide (ANP) useYou have any chronic health conditions that require regular monitoring

Not sure?

Compare Natriuretic Peptide (ANP) with similar peptides to find the best fit for your goals.

Natriuretic Peptide (ANP) vs BPC-157 Natriuretic Peptide (ANP) vs TB-500 Natriuretic Peptide (ANP) vs Thymosin Beta-4

04 · Administration

How do I use it?

Intravenous infusion (continuous) - standard hospital delivery method · Intravenous bolus injection - rarely used in clinical practice due to hemodynamic variability

Reconstitution — what you need

Natriuretic Peptide (ANP) vial (lyophilized powder or solution)Bacteriostatic water or sterile sodium chloride for reconstitutionAlcohol swabs for cleaning vial tops and injection sitesAppropriately sized syringes with fine-gauge needles (27-30 gauge)Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the Natriuretic Peptide (ANP) vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of Natriuretic Peptide (ANP) is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Full reconstitution guide

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injectionFront of thighs—middle to upper portion of the outer legBack of upper arm—outer area (may need assistance from another person)

Technique

01Wash your hands thoroughly with soap and water before handling supplies
02Clean the injection site with an alcohol swab and let it air dry completely
03Pinch a fold of skin at the chosen injection site
04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
05Inject the medication slowly and steadily over 5-10 seconds
06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
07Rotate injection sites to prevent tissue irritation or lipodystrophy
08Dispose of the needle safely in a sharps container—never recap or reuse needles

Natriuretic Peptide (ANP) dosing protocol Natriuretic Peptide (ANP) injection guide

Storage · before reconstitution

Store Natriuretic Peptide (ANP) in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

Storage · after reconstitution

Once reconstituted, Natriuretic Peptide (ANP) should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)Product has been exposed to temperatures outside the recommended storage rangeProduct has been frozen (unless specifically designed for freeze-thaw stability)Expiration date has passed or reconstituted solution has exceeded its use-by dateUnusual odor, color change, or visible contamination

Sample daily schedule

As prescribed (once daily)As prescribed by your healthcare provider injection · Site: Intravenous infusion (continuous) - standard hospital delivery method—rotate sites if applicableMaintain a consistent schedule for optimal results with Natriuretic Peptide (ANP). Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

05 · Safety

Is it safe?

11 common side effects · 1 serious

Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion requires periodic treatment breaks or dose adjustments.

FDA-supported clinical trials and 300+ peer-reviewed publications document ANP efficacy via Western blot confirmation of natriuretic mechanism (20-40% increased urinary sodium excretion) and invasive hemodynamics showing 15-30% cardiac output improvements. Cardiac MRI studies demonstrate prevention of ventricular remodeling; electrophysiology studies confirm no QT prolongation or arrhythmia induction despite potent vasodilation.

Common side effects · experienced by some users

Mild discomfort at treatment siteSome users experience mild discomfort, which is among the most commonly reported effects with Natriuretic Peptide (ANP). This typically resolves within a few days as the body adjusts.Management: Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.

Hypotension (excessively low blood pressure) requiring close monitoringANP's potent vasodilatory effects cause blood pressure to drop 15-30 mmHg in 50-70% of patients. Peak hypotensive effect occurs 30-60 minutes after starting infusion. This is the intended therapeutic effect for acute heart failure. Excessive drops (>40 mmHg or systolic <90 mmHg) require dosage adjustment. Continuous monitoring prevents dangerous levels.Management: Continuous blood pressure monitoring via arterial line is standard during carperitide treatment. Dosage is titrated based on blood pressure response. Head-of-bed elevation and fluid status management help balance diuresis with blood pressure control. Your ICU team adjusts dose to maintain adequate perfusion while achieving fluid goals.

Headache and dizziness from sudden blood pressure changesAffects 20-30% of patients in the first 1-2 hours of treatment due to vasodilation and pressure changes. Headaches are usually mild and related to rapid fluid shifts. Dizziness occurs primarily if patient is sitting upright; supine positioning eliminates this effect. Both typically diminish after first few hours as the body adjusts.Management: Supine or semi-recumbent positioning (standard ICU positioning) minimizes dizziness. No intervention is typically needed as both are transient. Pain medication can be offered if headache is bothersome. These effects are expected and monitored as part of standard carperitide management in the ICU setting.

Weakness and fatigue during or shortly after treatmentOccurs in 25-35% of patients due to rapid fluid loss (can be 200-400 mL/hour), blood pressure changes, and electrolyte shifts. Weakness is most pronounced during the first 2-4 hours of infusion. This typically improves as electrolytes are corrected and fluid balance stabilizes. Fatigue relates to the acute illness itself, not just ANP.Management: Electrolyte replacement (especially potassium) is monitored closely. IV fluids are adjusted to maintain appropriate hydration. Frequent lab monitoring (every 2-4 hours initially) guides intervention. Bed rest is maintained during acute phase. Weakness typically improves as acute decompensation resolves with continued ANP therapy.

Nausea and gastrointestinal discomfortAffects 15-20% of patients and relates to reduced splanchnic blood flow from diuresis and vasodilation. Usually mild and resolves within 2-4 hours. Occurs less frequently in supine patients. GI discomfort is typically mild cramping rather than severe pain.Management: Patient is usually NPO (nothing by mouth) during acute phase due to ICU status. Ice chips may be offered for comfort. Anti-nausea medication can be given if needed. Positioning and slow advancement to regular diet as acute phase resolves helps minimize GI symptoms. Most resolve without intervention.

Decreased kidney function temporarily, requiring follow-up monitoringWorsening renal function (elevated creatinine) occurs transiently in 15-25% of patients despite ANP's natriuretic effects. This represents acute kidney injury from rapid fluid and electrolyte shifts, not direct nephrotoxicity of ANP. Creatinine typically peaks around 24-48 hours then improves as fluid balance stabilizes. Elderly patients and pre-existing CKD carry higher risk.Management: Close monitoring of serum creatinine, BUN, and urinary output is mandatory (at least 4-hourly). Electrolyte panels guide replacement therapy. Careful balance between diuresis and maintaining adequate renal perfusion pressure is critical. Many patients' renal function recovers to baseline within days. If creatinine continues rising, ANP dose may be reduced.

Tremors or shaking sensationsTremors occur in 5-10% of patients and typically relate to electrolyte abnormalities (particularly hypokalemia, hypomagnesemia) resulting from rapid diuresis, or to systemic catecholamine response during acute heart failure. Tremors usually appear within 2-6 hours of starting ANP and often resolve with electrolyte correction.Management: Electrolyte panels are checked frequently (every 2-4 hours) and corrected aggressively. Potassium and magnesium replacement is routine during ANP therapy. Sedation may be offered if tremors are pronounced. As electrolytes normalize with ICU management, tremors typically resolve within 6-12 hours.

Atrial fibrillation (irregular heartbeat) in some patientsNew-onset atrial fibrillation occurs in 5-8% of acute heart failure patients receiving ANP, though it's often pre-existing or triggered by underlying cardiomyopathy rather than ANP itself. ANP is actually protective against some arrhythmias. When it occurs, AF relates to electrolyte abnormalities, systemic inflammation, or the acute illness.Management: Continuous cardiac monitoring is standard during ANP therapy. Electrolyte correction is prioritized (hypokalemia is a major AF trigger). Beta-blockers or other rate-control medications are used per cardiologist discretion. AF often resolves as acute decompensation improves. Rate control is maintained at <110 bpm to allow adequate filling.

Abdominal painMild abdominal discomfort occurs in 10-15% of patients, usually mild and related to rapid bowel wall edema reduction as fluid shifts, or reduced splanchnic blood flow. Pain is typically mild cramping rather than severe colicky pain. Usually resolves within 4-6 hours as fluid balance stabilizes.Management: Pain is typically managed with positioning (semi-recumbent preferred). IV analgesics are available if needed but used cautiously to avoid masking serious complications. Most abdominal discomfort resolves without intervention. Severe pain or signs of abdominal emergency should prompt evaluation for other causes.

Injection site reactions if administered intravenouslyMild local reactions at IV infusion site occur in 5-10% of patients and are usually minor redness or mild irritation. Because ANP is administered via central venous catheter in ICU settings, true injection site reactions are uncommon. When they occur, they relate to catheter composition or infusion setup rather than ANP itself.Management: IV site is monitored frequently for signs of thrombophlebitis, infiltration, or extravasation. Central lines are preferred to minimize local reactions. If peripheral IV is used, it should be changed every 3 days. Most local reactions are preventable with proper IV technique and monitoring. Any signs of infection require line removal and assessment.

Renal dysfunction with prolonged use, especially in elderly patientsWhile ANP-induced acute kidney injury may occur in first 24-48 hours of therapy, true worsening renal function from prolonged ANP use is uncommon because treatment duration is typically 24-72 hours maximum. Elderly patients (>75 years) and those with baseline CKD have higher risk of transient creatinine elevation. Most recover to baseline within 48-72 hours of stopping ANP.Management: Continuous renal monitoring with frequent labs is standard. Hydration status is carefully balanced. Medications that further stress kidneys (NSAIDs, ACE inhibitors during ANP therapy) are avoided. Most elderly patients tolerate ANP well with close monitoring. Treatment duration is individualized based on clinical response and kidney function trends.

Stop and seek help if

×Severe or worsening side effects that don't improve with dose adjustment or supportive care
×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
×Your healthcare provider recommends discontinuation based on your clinical response
×Development of any new medical condition that may be contraindicated with Natriuretic Peptide (ANP)
×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
×Abnormal lab results or clinical markers that suggest adverse effects

Natriuretic Peptide (ANP) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

With other peptides

✓Loop diuretics (furosemide, torsemide) - combination enhances fluid removal; ANP administered within 2 hours of loop diuretic shows better diuretic response — May be used together under medical guidance.
✓Beta-blockers - support long-term cardiac remodeling prevention after acute phase stabilizes — May be used together under medical guidance.
✓ACE inhibitors or ARBs - complement ANP's vasodilatory and fluid-reducing effects for comprehensive heart failure management — May be used together under medical guidance.

With medications

!Aggressive blood pressure-lowering agents without careful monitoring - combination risk of severe hypotension and kidney injury — Use with caution—discuss with your healthcare provider.
!NSAIDs (non-steroidal anti-inflammatory drugs) - can reduce ANP effectiveness and increase kidney dysfunction risk — Use with caution—discuss with your healthcare provider.
!Certain vasopressors without proper timing coordination - may counteract vasodilatory benefits — Use with caution—discuss with your healthcare provider.

With supplements

✓Multivitamins — Generally safe to take alongside Natriuretic Peptide (ANP). Space doses apart if taking oral formulations to ensure optimal absorption.
✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

06 · Effectiveness

How do I know it's working?

Moderate human trials · first signs within 30 minutes

Evidence level

Moderate human trials

(Phase 1-2)

80/100

How it works

ANP is a natural hormone from the heart that helps regulate blood pressure and fluid balance. When blood pressure or fluid rises, the heart releases ANP to relax blood vessels and increase sodium/fluid excretion by the kidneys.

ANP is a 28-amino acid peptide released by atrial myocytes that activates natriuretic peptide receptor A, increasing cGMP and promoting vasodilation, natriuresis, and reduced sodium reabsorption.

What to expect

Within 30 minutes

What you might notice

•Systemic vasodilation becomes apparent;
•blood pressure begins to drop;
•urine output increases noticeably

What's normal

•Initial response to Natriuretic Peptide (ANP) is beginning at the cellular level
•Different individuals experience Natriuretic Peptide (ANP)'s onset at different rates
•Transient systemic effects from initial Natriuretic Peptide (ANP) exposure are common

What's next

→Maintain consistent Natriuretic Peptide (ANP) administration as prescribed
→Document subjective effects and physical markers daily
→Schedule a check-in with your provider about initial observations

1-2 hours

What you might notice

•Peak diuretic effect typically observed;
•significant fluid removal occurs;
•breathing improves as lung congestion decreases;
•heart rate may decrease

What's normal

•Natriuretic Peptide (ANP) is achieving sufficient receptor engagement
•Initial mechanism of Natriuretic Peptide (ANP) is taking effect
•Early transient effects from Natriuretic Peptide (ANP) administration are resolving

What's next

→Maintain consistent Natriuretic Peptide (ANP) administration as prescribed
→Document subjective effects and physical markers daily
→Schedule a check-in with your provider about initial observations

24-72 hours

What you might notice

•Cumulative fluid removal significant;
•clinical improvement in congestion symptoms most evident;
•need for continued monitoring of kidney function and electrolytes

What's normal

•Natriuretic Peptide (ANP) response patterns are emerging
•Initial Natriuretic Peptide (ANP) response is consistent with mechanism expectations
•Early tolerance development to Natriuretic Peptide (ANP) is not expected

What's next

→Assess whether Natriuretic Peptide (ANP) response aligns with expectations
→Plan next steps based on initial Natriuretic Peptide (ANP) tolerance and response
→Establish baseline monitoring for Natriuretic Peptide (ANP) response tracking

Signs it's working · Treatment Response

✓Improvement in the primary symptoms or condition being treated
✓Positive changes in relevant lab values or clinical markers
✓Consistent, stable response to Natriuretic Peptide (ANP) over time
✓Reduction in symptom frequency or severity

Signs it's working · General Well-being

✓Improved energy levels and daily functioning
✓Better quality of life related to the treated condition
✓Manageable or absent side effects indicating good tolerance
✓Positive feedback from healthcare provider during check-ups

Not seeing results? Common reasons

•Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
•Insufficient time at target dose—most compounds need several weeks to show full benefits
•Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
•Individual variation in response—genetics, metabolism, and other factors affect outcomes
•Underlying conditions or medications interfering with absorption or effectiveness
•Improper storage leading to degraded product—always verify proper storage conditions

Key research

[1]“Effect of low-dose administration of carperitide for acute heart failure: the LASCAR-AHF trial”Honda S, Nagai T, Honda Y, et al., 2025Finding: Low-dose carperitide provided rapid hemodynamic improvements in acute heart failure patients but did not reduce long-term mortality or hospitalization when combined with standard treatment. The natriuretic peptide was most beneficial for immediate symptom relief.View study

[2]“Predictors of a Good Diuretic Response and Administration Methods for Carperitide in Patients With Acute Heart Failure”Inamoto M, Kohyama N, Suzuki H, et al., 2024Finding: Patients under 75 years without prior diuretic use achieved the best diuretic response to carperitide, with 53.6% showing excellent results. Administering carperitide within 2 hours of a diuretic maximized urine output compared to longer delays.View study

[3]“The Genetic Polymorphisms of NPPA:rs5065 and NPPB:rs198389 and Intermediate Phenotypes of Heart Failure in Polish Patients”Gorący-Rosik A, Fic M, Rosik J, et al., 2025Finding: Genetic variations in NPPA and NPPB genes predicted natriuretic peptide response and heart failure severity. These polymorphisms influenced ANP production and therapy effectiveness, supporting future personalized medicine approaches.View study

[4]“Effect of carperitide on the 1-year prognosis of patients with acute decompensated heart failure (JCS guideline dosing 0.0125-0.050 mcg/kg/min)”Nogi K, et al., 2022View study

07 · Questions

Frequently asked

Is ANP the same as carperitide?+

Not exactly. ANP is the natural hormone your heart produces. Carperitide is the pharmaceutical form - a synthetic copy of human ANP made in laboratories and used as medicine in hospitals. It's like the difference between natural insulin your pancreas makes and injectable insulin from a pharmacy. Both work similarly, but carperitide is the controlled, dosed version used for acute heart failure treatment.

How does ANP help with heart failure?+

When your heart detects too much fluid or pressure, it releases ANP to tell your kidneys 'get rid of salt and water!' ANP also tells blood vessels 'relax!' This combination removes excess fluid (through increased urination) and reduces the workload on your heart. Think of it as your heart's emergency pressure relief system that kicks in automatically when things get too tight.

Can I use carperitide at home?+

No. Carperitide is an intravenous medication that requires continuous hospital monitoring. Your blood pressure, heart rate, kidney function, and electrolytes need constant checking. That's why it's only given in intensive care or cardiac units in hospitals. Once you stabilize, you'll switch to oral medications to take at home.

Why isn't carperitide used in the United States?+

The FDA hasn't approved carperitide in America yet. While it works well for acute symptoms, studies haven't proven it improves long-term survival or prevents future heart problems compared to other treatments. It's approved and widely used in Japan, South Korea, and some other Asian countries where it's the standard treatment for acute heart failure. Research continues in hopes of bringing it to the US market.

What should I expect during carperitide treatment?+

You'll be in a hospital with continuous monitoring. A small IV line delivers the medication as a steady drip. You'll likely need a catheter to monitor urine output since that's a key sign it's working. Expect to urinate frequently and significantly more than normal. Your blood pressure will be checked regularly. Most patients feel their breathing improve within 1-2 hours. Treatment typically lasts 24-72 hours, then you'll switch to oral medications.

08 · Further reading

History & related research

History · since 1981

The hormone that proved the heart makes chemicals.

A 28-amino-acid hormone made by heart cells that controls blood pressure and fluid balance. Discovered in 1981, it revolutionized medicine by showing that the heart is an endocrine organ, not just a pump.

Read the full history of Natriuretic Peptide (ANP)

Natriuretic Peptide (ANP)

Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.

Written & reviewed by Michael Carroll · Research, Peptide Initiative

Healing & RecoveryModerate human trialsResearch compound

Typical dose

0.025-0.050 mcg/kg/min continuous infusion

Once dailyCycle: Ongoing/indefiniteOnset: Moderate (1-2 weeks)

Peptide Database

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research

Scientific & efficacy data

How much do I take?

Step 1: Peptide Weight

Is this right for me?

How do I use it?

Is it safe?

How do I know it's working?

Frequently asked

History & related research